Recently, data concerning the inhibition of RCC growth and metastasis via AKT/mammalian target of rapamycin, ERK and JAK2/STAT3 pathway inhibition induced by simvastatin have opened a novel therapeutic perspective for these patients [94], also these data should be confirmed in randomized trials. Here, MTOR is linked to renal cell carcinoma.